DXCM vs TRAK · P/E 63, rev $2.50B vs P/E 25, rev $17.7M
DexCom Inc (DXCM) versus ReposiTrak (TRAK) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
ReposiTrak (TRAK) is a software - application company listed on NYSE.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported TRAK revenue for 2026-03-31 was $17.7M. Net income was $5.5M. Revenue was up 49.7% from 2025-12-31 to 2026-03-31. TRAK currently screens at market cap $167.9M and trailing P/E 25.0.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. TRAK currently screens at market cap $167.9M and trailing P/E 25.0.
Not investment advice. Open the DXCM and TRAK stock pages for the full models.
Not investment advice.